IQVIA Holdings trades in a tight range, technicals flag cautious signal for the shares

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-23, 13:25.

IQVIA Holdings (US46266C1053) starts the new week on the NYSE with a relatively stable share price around the upper 160 dollar area. The focus for investors this Tuesday is the mix of cautious technical signals and a still constructive analyst consensus on the stock.

What recent data show

IQVIA shares last closed at 167.82 US dollars on 22 June in New York trading, giving the company a market capitalization of about 28.0 billion dollars according to TradingKey data. TradingKey quotes IQVIA at 167.82 dollars with a 28.01 billion dollar market cap. That closing level reflects a marginal 0.03 percent gain on the day, underlining how muted the short-term price action has been.

The shares trade on the NYSE under the ticker IQV and sit in the broader S&P 500 healthcare universe alongside peers such as Charles River Laboratories and Thermo Fisher Scientific. In valuation terms, TradingKey reports a trailing price-earnings ratio of 20.66, placing IQVIA roughly in line with established contract research and healthcare data peers on a multiples basis. The same TradingKey overview lists the P/E at 20.66.

Analyst views and consensus

Despite the subdued share price pattern in recent sessions, analyst sentiment on IQVIA remains broadly constructive. According to the current TradingKey consensus, the stock carries an overall rating of Buy with an average price target of 228.36 dollars, implying notable upside from the latest close. TradingKey summarizes the consensus rating as Buy with a 228.36 dollar target. That target range reflects expectations for continued demand in clinical research outsourcing and healthcare analytics.

The contract research organization segment has been volatile in 2026, particularly after increased attention on AI tools for drug discovery and trial optimization. TradingKey notes that sector names including IQVIA and Charles River Laboratories came under pressure earlier in the year when life-science-focused AI platforms gained prominence, although IQVIA has since stabilized in the mid-160 dollar zone. The TradingKey sector commentary cites a 3.5 percent decline for IQVIA during an April CRO sell-off.

How the business earns money

IQVIA generates its revenue primarily by providing clinical research services and data analytics to pharmaceutical, biotechnology and medical device companies. It designs and runs clinical trials, manages real-world evidence studies and offers technology platforms that help clients plan, execute and monitor global development programs across multiple therapeutic areas.

Where the shares trade now

The IQVIA Holdings shares (US46266C1053) last traded on 2026-06-22 at 16:00 Eastern Time on the NYSE at 167.82 US dollars.

This article is for informational purposes only and does not constitute investment advice, an offer, or a solicitation to buy or sell any securities. Investors should conduct their own research and, where appropriate, consult a qualified financial adviser.